Psychedelic Spotlight speaks to a Field Trip Health patient and a psychotherapist, whose experiences suggest ketamine can also treat anxiety among other mental health issues.
Mind Medicine Australia, a psychedelics advocacy organization that filed the application, says the country “lost a massive opportunity to be a leader in this field with this decision.”
This week in psychedelic business news: MAPS pioneers new funding structure; FDA green lights a Cybin study for Covid-19 distress; Compass Pathways gets new majority stakeholder.
Drug Enforcement Agency also addresses concerns from Native American Church regarding peyote poaching for mescaline research.
Mixing psychedelics goes by many names in pop culture: hippie flipping (MDMA and mushrooms) and candy flipping (MDMA and LSD), to name two. Depending on how you go about it, the experience can be life-affirmingly euphoric or severely overwhelming. But is it ever worth the risk?
“It’s time for psychedelic medicine to climb down from the ivory tower and into the community,” says Cybin Chief Clinical Officer Dr. Alex Belser.
“People will continue to kill themselves, and my patient will continue to suffer in silence until the Victorian Government allows me to access a new treatment which may finally bring peace to a troubled mind,” says Dr. Eli Kotler.
Drug Enforcement Agency also hugely boosts MDMA and DMT quotas “in response to the nationwide public interest in hallucinogenic controlled substances research.”
Rick Doblin’s organization partners with Numinus Wellness to manage the Canadian sites where therapists will be administering the psychedelic therapy.
“This treatment is the reason that my son has a father instead of a folded flag,” a once-suicidal Iraq War veteran tells Savannah Guthrie.
End of content
End of content
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.